




# A global leader in digital health

At ResMed, we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries.

Diversified revenue by business and by geography (LTM 3Q24)




Revenue (\$B)

13% CAGR




Non-GAAP Operating Income (\$B)

15% CAGR



Non-GAAP EPS

15% CAGR



140+

COUNTRIES SERVED

24.5M+

CLOUD-CONNECTABLE DEVICES

174M+

LIVES CHANGED, LAST 12 MONTHS

18B+

NIGHTS OF MEDICAL SLEEP & RESPIRATORY DATA

~6%

REINVESTED IN R&D

9,700+

PATENTS AND DESIGNS

(9)% 1-yr

5% 3-yr

99% 5-yr

TOTAL SHAREHOLDER RETURN (as of March 31, 2024)



Mick Farrell named #1 Health Technology CEO of 2022



Named one of America's top 500 "Most Responsible Companies" in (2021, 2022, 2023, 2024)



Named one of the "Management Top 250" companies in (2020, 2021, 2022, 2023); top 25 among healthcare companies

## Sleep health

~**936 million people** live with sleep apnea – the upper airway closes off causing the body to jolt “awake” to take breaths throughout the night.<sup>1</sup>

~**870 million people** live with insomnia.<sup>2</sup>

**ResMed provides: CPAP therapy that’s smaller, quieter, more comfortable, and more connected – and in Germany, a reimbursed Digital Health Application (DiGA) for insomnia.**

- **39% lower all-cause mortality rate** when treating sleep apnea with CPAP<sup>3</sup>
- **87% patient adherence** on CPAP therapy when remotely and self monitored<sup>4</sup>



77% with obesity<sup>5</sup>




76% with heart failure<sup>6</sup>



72% with type 2 diabetes<sup>7</sup>

**ALSO HAVE SLEEP APNEA**

**85-90% OF COPD CASES ARE CAUSED BY CIGARETTE SMOKING<sup>8</sup>**



## COPD/asthma/lung disease

An estimated **480 million people** live with chronic obstructive pulmonary disease,<sup>9</sup> the world’s third leading killer.<sup>10</sup>

**Over 330 million people** live with asthma.<sup>11</sup>

**ResMed provides: The world’s most complete digital solution suite throughout a patient’s journey.**

- **76% reduced risk of one-year death** for COPD patients using non-invasive ventilation (NIV)<sup>12</sup>

Propeller Health’s Digital Therapeutic Platform resulted in:

- **58% higher medication adherence**<sup>13</sup>
- **57% fewer asthma-related** emergency visits and hospitalizations<sup>14</sup>
- **35% fewer COPD-related** emergency visits and hospitalizations<sup>15</sup>

## SaaS

More people want to **age in place** and **receive affordable, high-quality care** outside the hospital.

**ResMed provides: Comprehensive cloud-based clinical, financial, and operational solutions that support healthcare providers across a range of care settings outside of the hospital.**

**MatrixCare**  
by ResMed

**brightree**  
by ResMed

**MEDIFOX DAN**

### US Market



Home medical equipment (HME) providers



Home infusion pharmacy



Home health



Hospice



Skilled nursing facilities



Life plan communities



Senior living



Private duty

### German Market



Ambulant (Similar to US home health)



Stationär (Similar to US nursing homes)



Youth & disabled care



Outpatient therapy



Non-professional care

## Contact

**Media:** news@resmed.com **Investors:** investorrelations@resmed.com



<sup>1</sup> Benjfield AV et al. *Lancet Respir Med* 2019 <sup>2</sup> ResMed internal estimate. <sup>3</sup> Pepin JL et al. *Chest* 2022 <sup>4</sup> Malhotra A et al. *Chest* 2018 <sup>5</sup> O’Keeffe T and Patterson EJ. *Obes Surg* 2004 <sup>6</sup> Oldenburg O et al. *Eur J Heart Fail* 2007 <sup>7</sup> Einhorn D et al. *Endocr Pract* 2007 <sup>8</sup> Amer Lung Assoc <https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/what-causes-copd>. Accessed Jun 19, 2020. <sup>9</sup> Boers E et al. *ERJ Suppl* (ERS Congress late-breaking abstract) 2022 <sup>10</sup> WHO. <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>. Accessed Jun 19, 2020. <sup>11</sup> The Global Asthma Report 2018. <http://globalasthmareport.org/burden/burden.php>. Accessed April 26, 2022. <sup>12</sup> Kohnlein T et al. *Lancet Respir Med* 2014 <sup>13</sup> Van Sickle D et al. *Eur Resp J* 2016 <sup>14</sup> Merchant R et al. *World Allergy Organ J* 2018 <sup>15</sup> Brazeal T et al. Abstract at European Respiratory Society 2021

Distributed by ResMed Corp, 9001 Spectrum Center Boulevard, San Diego, CA 92123 USA, (858) 836-5000 or (800) 424-0737 (toll-free). See ResMed.com for other ResMed locations worldwide. Specifications may change without notice. For patent and other intellectual property information, see ResMed.com/ip. © 2024 ResMed. Updated: April 25, 2024.

